AI assistant
PRESCIENT THERAPEUTICS LIMITED Call Transcript 2017
65622_rns_2017-04-19_c05ad89c-6eba-4bfb-a884-b5e80be52101.pdf
Call Transcript
Open in viewerOpens in your device viewer
ASX Release
AML Clinical Trial Update – Conference call with Principal Investigator
Melbourne, Australia (20 April 2017): Clinical-stage oncology company Prescient Therapeutics Ltd (ASX: PTX) is pleased to announce it will host a conference call for investors to provide an overview and update of its current Phase 1b trial of PTX-200 in Acute Myeloid Leukemia (AML).
The overview will be provided by globally renowned cancer researcher Professor Said Sebti, Chief Scientific Officer of Prescient Therapeutics Ltd, and the Principal Investigator, Professor Jeffrey Lancet, Chair of the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center. The call will include a live question and answer session.
The call will be held at:
Australia: 8.15am AEST Friday 28th April 2017
US PST: 3.15pm Thursday 27th April US EST: 6.15pm Thursday 27th April
| Conference ID: | 726413 |
|---|---|
| Australia Toll Free: | 1 800 558 698 |
| Australia Local: | 02 9007 3187 |
| New Zealand Toll Free: | 0800 453 055 |
| United States: | (855) 881 1339 |
| US Local (New York): | (914) 202 3258 |
| US Local (Los Angeles): | (909) 235 4020 |
| US Local (Chicago): | (815) 373 2080 |
| Canada: | 1855 8811 339 |
| France: | 0800 913 848 |
| Germany: | 0800 182 7617 |
| Hong Kong: | 800 966 806 |
| Japan: | 0053 116 1281 |
| Singapore: | 800 101 2785 |
| United Kingdom: | 0800 051 8245 |
ENDS
About Prescient Therapeutics Limited (PTX)
PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.
PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials. The first is a Phase 1b/2 trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt) and Yale Cancer Center in New Haven, Connecticut (Yale) under the leadership of Professor Jeffrey Lancet, MD.
PTX is also conducting a Phase 2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase 1b/2 trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.
PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.
Further enquiries:
Steven Yatomi-Clarke CEO & Managing Director Prescient Therapeutics Limited +61 417 601 440
Kyahn Williamson WE Buchan [email protected] +61 401 018 828